Nuvation Bio, Inc. (NUVB)
NYSEHealth CareBiotechnologySnapshot 2026-09-04
$6.81+0.59%
Close 2026-09-04 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NUVB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -66.0% |
| Our one-year growth estimate | diamond | 46.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 112.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
NUVB — earnings in line
Dated 2026-08-06
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On August 6, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the…
Why it matters: Updates on this study will indicate progress in a key development area for Nuvation Bio. Positive data could boost stock sentiment.
Supportive ifNuvation Bio shares good interim results from the Phase 3 SIGMA study.
Worry ifNuvation Bio reports delays or negative results from the Phase 3 SIGMA study.
Why it matters: An increase in revenue guidance shows management's confidence in growth. It can boost investor trust.
Supportive ifManagement expects to make more than $83.228 million in revenue for 2026.
Worry ifManagement keeps revenue guidance at or below $83.228 million for 2026.
Why it matters: Good results from the Phase 3 study could grow safusidenib's market. It may prove effective for IDH1-mutant gliomas.
Supportive ifThe Phase 3 study of safusidenib has good results. It shows strong effectiveness.
Worry ifThe Phase 3 study of safusidenib shows bad results. This raises worries about its effectiveness.
Why it matters: Positive net income would show a strong financial change. This could help investor feelings.
Supportive ifNuvation Bio reports a net income greater than $5.397 million in Q2 2026.
Worry ifNuvation Bio reports a net loss in Q2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$268 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $618 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,755 loss on $10,000 · 57.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Positive net income shows better financial health. It may draw more interest from investors.
Supportive ifNet income reported as positive in the next earnings release.
Worry ifNet income remains negative in the next earnings release.
Why it matters: Starting this study shows a commitment to safusidenib. It could expand its market.
Supportive ifThe Phase 3 study for safusidenib starts. This shows progress in clinical development.
Worry ifIf the Phase 3 study does not start by the end of 2026, it suggests delays.
Why it matters: A drop below this level may show financial strain or high spending without enough revenue.
Worry ifCash reserves are above $600 million. This shows strong financial health.
Less concerning ifCash reserves drop below $600 million. This may mean financial trouble.
Why it matters: Surpassing this revenue would show strong growth and adoption of IBTROZI in the market.
Supportive ifIn Q3, IBTROZI made over $30 million. This shows that it is still growing.
Worry ifIn Q3, IBTROZI made less than $23 million. This shows slower adoption.
Why it matters: The FDA's choice will affect how well IBTROZI does in advanced ROS1+ NSCLC.
Watch forThe FDA approves the sNDA for IBTROZI. This improves its label and market position.
Also watch forFDA denies or delays the sNDA for IBTROZI, impacting its market potential.